nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—Retching—Dextrothyroxine—hypothyroidism	0.0256	0.0404	CcSEcCtD
Sitaxentan—Retching—Levothyroxine—hypothyroidism	0.0256	0.0404	CcSEcCtD
Sitaxentan—Acute bronchitis—Liotrix—hypothyroidism	0.0246	0.0389	CcSEcCtD
Sitaxentan—CYP2C19—urine—hypothyroidism	0.0246	0.0841	CbGeAlD
Sitaxentan—Tracheobronchitis—Liotrix—hypothyroidism	0.0213	0.0336	CcSEcCtD
Sitaxentan—CYP2C9—urine—hypothyroidism	0.0191	0.0652	CbGeAlD
Sitaxentan—Retching—Liotrix—hypothyroidism	0.0188	0.0297	CcSEcCtD
Sitaxentan—EDNRB—adrenal cortex—hypothyroidism	0.0185	0.0632	CbGeAlD
Sitaxentan—Muscle twitching—Liothyronine—hypothyroidism	0.0181	0.0286	CcSEcCtD
Sitaxentan—EDNRB—heart—hypothyroidism	0.0179	0.0611	CbGeAlD
Sitaxentan—EDNRA—adrenal cortex—hypothyroidism	0.0153	0.0522	CbGeAlD
Sitaxentan—EDNRB—pituitary gland—hypothyroidism	0.0149	0.051	CbGeAlD
Sitaxentan—EDNRA—heart—hypothyroidism	0.0148	0.0505	CbGeAlD
Sitaxentan—CYP3A4—urine—hypothyroidism	0.0145	0.0497	CbGeAlD
Sitaxentan—Cardiac failure congestive—Liothyronine—hypothyroidism	0.0142	0.0225	CcSEcCtD
Sitaxentan—EDNRB—adrenal gland—hypothyroidism	0.0133	0.0456	CbGeAlD
Sitaxentan—EDNRB—thyroid gland—hypothyroidism	0.0129	0.044	CbGeAlD
Sitaxentan—EDNRB—female gonad—hypothyroidism	0.0124	0.0425	CbGeAlD
Sitaxentan—EDNRA—pituitary gland—hypothyroidism	0.0123	0.0422	CbGeAlD
Sitaxentan—Hypernatraemia—Liotrix—hypothyroidism	0.0122	0.0193	CcSEcCtD
Sitaxentan—Venous thrombosis—Liotrix—hypothyroidism	0.0119	0.0188	CcSEcCtD
Sitaxentan—EDNRB—testis—hypothyroidism	0.011	0.0377	CbGeAlD
Sitaxentan—EDNRA—adrenal gland—hypothyroidism	0.011	0.0377	CbGeAlD
Sitaxentan—Angina pectoris—Liothyronine—hypothyroidism	0.0109	0.0172	CcSEcCtD
Sitaxentan—EDNRA—thyroid gland—hypothyroidism	0.0106	0.0364	CbGeAlD
Sitaxentan—EDNRB—liver—hypothyroidism	0.0104	0.0356	CbGeAlD
Sitaxentan—EDNRA—female gonad—hypothyroidism	0.0103	0.0351	CbGeAlD
Sitaxentan—EDNRB—cerebellum—hypothyroidism	0.0102	0.0348	CbGeAlD
Sitaxentan—Acute coronary syndrome—Liothyronine—hypothyroidism	0.0098	0.0155	CcSEcCtD
Sitaxentan—Myocardial infarction—Liothyronine—hypothyroidism	0.00975	0.0154	CcSEcCtD
Sitaxentan—EDNRA—testis—hypothyroidism	0.00911	0.0312	CbGeAlD
Sitaxentan—Wheezing—Levothyroxine—hypothyroidism	0.00848	0.0134	CcSEcCtD
Sitaxentan—Wheezing—Dextrothyroxine—hypothyroidism	0.00848	0.0134	CcSEcCtD
Sitaxentan—Feeling hot—Liotrix—hypothyroidism	0.00818	0.0129	CcSEcCtD
Sitaxentan—Abscess—Liotrix—hypothyroidism	0.00812	0.0128	CcSEcCtD
Sitaxentan—Cellulitis—Liotrix—hypothyroidism	0.00706	0.0112	CcSEcCtD
Sitaxentan—Hypocalcaemia—Liotrix—hypothyroidism	0.00702	0.0111	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Levothyroxine—hypothyroidism	0.00699	0.011	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Dextrothyroxine—hypothyroidism	0.00699	0.011	CcSEcCtD
Sitaxentan—Increased appetite—Levothyroxine—hypothyroidism	0.00675	0.0107	CcSEcCtD
Sitaxentan—Increased appetite—Dextrothyroxine—hypothyroidism	0.00675	0.0107	CcSEcCtD
Sitaxentan—Muscle twitching—Liotrix—hypothyroidism	0.00654	0.0103	CcSEcCtD
Sitaxentan—Cardiac failure—Dextrothyroxine—hypothyroidism	0.00649	0.0103	CcSEcCtD
Sitaxentan—Hypoglycaemia—Dextrothyroxine—hypothyroidism	0.00649	0.0103	CcSEcCtD
Sitaxentan—Hypoglycaemia—Levothyroxine—hypothyroidism	0.00649	0.0103	CcSEcCtD
Sitaxentan—Cardiac failure—Levothyroxine—hypothyroidism	0.00649	0.0103	CcSEcCtD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PRL—hypothyroidism	0.00626	0.0835	CbGpPWpGaD
Sitaxentan—Wheezing—Liotrix—hypothyroidism	0.00624	0.00986	CcSEcCtD
Sitaxentan—Tachycardia—Liothyronine—hypothyroidism	0.00619	0.00978	CcSEcCtD
Sitaxentan—Fluid retention—Liotrix—hypothyroidism	0.0061	0.00964	CcSEcCtD
Sitaxentan—Hypotension—Liothyronine—hypothyroidism	0.00593	0.00937	CcSEcCtD
Sitaxentan—Dehydration—Dextrothyroxine—hypothyroidism	0.00589	0.00932	CcSEcCtD
Sitaxentan—Dehydration—Levothyroxine—hypothyroidism	0.00589	0.00932	CcSEcCtD
Sitaxentan—Muscular weakness—Dextrothyroxine—hypothyroidism	0.00559	0.00883	CcSEcCtD
Sitaxentan—Muscular weakness—Levothyroxine—hypothyroidism	0.00559	0.00883	CcSEcCtD
Sitaxentan—Angina pectoris—Levothyroxine—hypothyroidism	0.00534	0.00843	CcSEcCtD
Sitaxentan—Angina pectoris—Dextrothyroxine—hypothyroidism	0.00534	0.00843	CcSEcCtD
Sitaxentan—Cardiac failure congestive—Liotrix—hypothyroidism	0.00514	0.00812	CcSEcCtD
Sitaxentan—Body temperature increased—Liothyronine—hypothyroidism	0.00501	0.00793	CcSEcCtD
Sitaxentan—Increased appetite—Liotrix—hypothyroidism	0.00496	0.00784	CcSEcCtD
Sitaxentan—Weight decreased—Dextrothyroxine—hypothyroidism	0.00496	0.00783	CcSEcCtD
Sitaxentan—Weight decreased—Levothyroxine—hypothyroidism	0.00496	0.00783	CcSEcCtD
Sitaxentan—Renal impairment—Liotrix—hypothyroidism	0.0049	0.00774	CcSEcCtD
Sitaxentan—CYP2C9—heart—hypothyroidism	0.00489	0.0167	CbGeAlD
Sitaxentan—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.00481	0.00761	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.00481	0.00761	CcSEcCtD
Sitaxentan—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.00479	0.00757	CcSEcCtD
Sitaxentan—Myocardial infarction—Levothyroxine—hypothyroidism	0.00479	0.00757	CcSEcCtD
Sitaxentan—Hypoglycaemia—Liotrix—hypothyroidism	0.00478	0.00755	CcSEcCtD
Sitaxentan—Cardiac failure—Liotrix—hypothyroidism	0.00478	0.00755	CcSEcCtD
Sitaxentan—CYP2C19—blood—hypothyroidism	0.0047	0.0161	CbGeAlD
Sitaxentan—CYP2C9—cardiovascular system—hypothyroidism	0.00461	0.0158	CbGeAlD
Sitaxentan—EDNRB—Peptide GPCRs—TSHR—hypothyroidism	0.0046	0.0614	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PRL—hypothyroidism	0.00448	0.0598	CbGpPWpGaD
Sitaxentan—Blood creatinine increased—Liotrix—hypothyroidism	0.00437	0.0069	CcSEcCtD
Sitaxentan—Dehydration—Liotrix—hypothyroidism	0.00434	0.00685	CcSEcCtD
Sitaxentan—Muscular weakness—Liotrix—hypothyroidism	0.00411	0.0065	CcSEcCtD
Sitaxentan—Flushing—Levothyroxine—hypothyroidism	0.00407	0.00643	CcSEcCtD
Sitaxentan—Flushing—Dextrothyroxine—hypothyroidism	0.00407	0.00643	CcSEcCtD
Sitaxentan—Angina pectoris—Liotrix—hypothyroidism	0.00392	0.0062	CcSEcCtD
Sitaxentan—Bronchitis—Liotrix—hypothyroidism	0.00387	0.00612	CcSEcCtD
Sitaxentan—Alopecia—Dextrothyroxine—hypothyroidism	0.00387	0.00612	CcSEcCtD
Sitaxentan—Alopecia—Levothyroxine—hypothyroidism	0.00387	0.00612	CcSEcCtD
Sitaxentan—Tension—Dextrothyroxine—hypothyroidism	0.00375	0.00592	CcSEcCtD
Sitaxentan—Tension—Levothyroxine—hypothyroidism	0.00375	0.00592	CcSEcCtD
Sitaxentan—Nervousness—Dextrothyroxine—hypothyroidism	0.00371	0.00586	CcSEcCtD
Sitaxentan—Nervousness—Levothyroxine—hypothyroidism	0.00371	0.00586	CcSEcCtD
Sitaxentan—CYP2C19—liver—hypothyroidism	0.00368	0.0126	CbGeAlD
Sitaxentan—CYP2C9—blood—hypothyroidism	0.00365	0.0125	CbGeAlD
Sitaxentan—Weight decreased—Liotrix—hypothyroidism	0.00365	0.00576	CcSEcCtD
Sitaxentan—Tremor—Levothyroxine—hypothyroidism	0.00358	0.00565	CcSEcCtD
Sitaxentan—Tremor—Dextrothyroxine—hypothyroidism	0.00358	0.00565	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Liotrix—hypothyroidism	0.00354	0.0056	CcSEcCtD
Sitaxentan—Renal failure—Liotrix—hypothyroidism	0.00353	0.00558	CcSEcCtD
Sitaxentan—Myocardial infarction—Liotrix—hypothyroidism	0.00352	0.00557	CcSEcCtD
Sitaxentan—Agitation—Dextrothyroxine—hypothyroidism	0.00351	0.00554	CcSEcCtD
Sitaxentan—Agitation—Levothyroxine—hypothyroidism	0.00351	0.00554	CcSEcCtD
Sitaxentan—EDNRA—Peptide GPCRs—TSHR—hypothyroidism	0.00329	0.0439	CbGpPWpGaD
Sitaxentan—Confusional state—Dextrothyroxine—hypothyroidism	0.00314	0.00496	CcSEcCtD
Sitaxentan—Confusional state—Levothyroxine—hypothyroidism	0.00314	0.00496	CcSEcCtD
Sitaxentan—Tachycardia—Levothyroxine—hypothyroidism	0.00304	0.00481	CcSEcCtD
Sitaxentan—Tachycardia—Dextrothyroxine—hypothyroidism	0.00304	0.00481	CcSEcCtD
Sitaxentan—Flushing—Liotrix—hypothyroidism	0.00299	0.00473	CcSEcCtD
Sitaxentan—CYP2C9—liver—hypothyroidism	0.00285	0.00975	CbGeAlD
Sitaxentan—Alopecia—Liotrix—hypothyroidism	0.00285	0.0045	CcSEcCtD
Sitaxentan—Insomnia—Dextrothyroxine—hypothyroidism	0.00282	0.00445	CcSEcCtD
Sitaxentan—Insomnia—Levothyroxine—hypothyroidism	0.00282	0.00445	CcSEcCtD
Sitaxentan—CYP3A4—blood—hypothyroidism	0.00278	0.00951	CbGeAlD
Sitaxentan—Tension—Liotrix—hypothyroidism	0.00275	0.00435	CcSEcCtD
Sitaxentan—Nervousness—Liotrix—hypothyroidism	0.00273	0.00431	CcSEcCtD
Sitaxentan—Fatigue—Levothyroxine—hypothyroidism	0.00269	0.00424	CcSEcCtD
Sitaxentan—Fatigue—Dextrothyroxine—hypothyroidism	0.00269	0.00424	CcSEcCtD
Sitaxentan—Tremor—Liotrix—hypothyroidism	0.00263	0.00416	CcSEcCtD
Sitaxentan—Agitation—Liotrix—hypothyroidism	0.00258	0.00408	CcSEcCtD
Sitaxentan—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00257	0.00406	CcSEcCtD
Sitaxentan—Feeling abnormal—Levothyroxine—hypothyroidism	0.00257	0.00406	CcSEcCtD
Sitaxentan—Urticaria—Levothyroxine—hypothyroidism	0.00247	0.00391	CcSEcCtD
Sitaxentan—Urticaria—Dextrothyroxine—hypothyroidism	0.00247	0.00391	CcSEcCtD
Sitaxentan—Body temperature increased—Levothyroxine—hypothyroidism	0.00246	0.00389	CcSEcCtD
Sitaxentan—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00246	0.00389	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—TRH—hypothyroidism	0.00246	0.0328	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—TRH—hypothyroidism	0.00243	0.0324	CbGpPWpGaD
Sitaxentan—Chest pain—Liotrix—hypothyroidism	0.00239	0.00378	CcSEcCtD
Sitaxentan—Confusional state—Liotrix—hypothyroidism	0.00231	0.00365	CcSEcCtD
Sitaxentan—Oedema—Liotrix—hypothyroidism	0.00229	0.00362	CcSEcCtD
Sitaxentan—Infection—Liotrix—hypothyroidism	0.00228	0.0036	CcSEcCtD
Sitaxentan—Tachycardia—Liotrix—hypothyroidism	0.00224	0.00353	CcSEcCtD
Sitaxentan—Asthenia—Dextrothyroxine—hypothyroidism	0.00223	0.00353	CcSEcCtD
Sitaxentan—Asthenia—Levothyroxine—hypothyroidism	0.00223	0.00353	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.0022	0.0293	CbGpPWpGaD
Sitaxentan—Anorexia—Liotrix—hypothyroidism	0.00218	0.00345	CcSEcCtD
Sitaxentan—CYP3A4—liver—hypothyroidism	0.00217	0.00743	CbGeAlD
Sitaxentan—Hypotension—Liotrix—hypothyroidism	0.00214	0.00338	CcSEcCtD
Sitaxentan—Diarrhoea—Levothyroxine—hypothyroidism	0.00213	0.00337	CcSEcCtD
Sitaxentan—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00213	0.00337	CcSEcCtD
Sitaxentan—Insomnia—Liotrix—hypothyroidism	0.00207	0.00328	CcSEcCtD
Sitaxentan—Decreased appetite—Liotrix—hypothyroidism	0.00199	0.00315	CcSEcCtD
Sitaxentan—Vomiting—Dextrothyroxine—hypothyroidism	0.00198	0.00313	CcSEcCtD
Sitaxentan—Vomiting—Levothyroxine—hypothyroidism	0.00198	0.00313	CcSEcCtD
Sitaxentan—Fatigue—Liotrix—hypothyroidism	0.00198	0.00312	CcSEcCtD
Sitaxentan—Rash—Levothyroxine—hypothyroidism	0.00196	0.0031	CcSEcCtD
Sitaxentan—Rash—Dextrothyroxine—hypothyroidism	0.00196	0.0031	CcSEcCtD
Sitaxentan—Dermatitis—Dextrothyroxine—hypothyroidism	0.00196	0.0031	CcSEcCtD
Sitaxentan—Dermatitis—Levothyroxine—hypothyroidism	0.00196	0.0031	CcSEcCtD
Sitaxentan—Constipation—Liotrix—hypothyroidism	0.00196	0.0031	CcSEcCtD
Sitaxentan—Headache—Levothyroxine—hypothyroidism	0.00195	0.00308	CcSEcCtD
Sitaxentan—Headache—Dextrothyroxine—hypothyroidism	0.00195	0.00308	CcSEcCtD
Sitaxentan—Feeling abnormal—Liotrix—hypothyroidism	0.00189	0.00298	CcSEcCtD
Sitaxentan—Nausea—Dextrothyroxine—hypothyroidism	0.00185	0.00292	CcSEcCtD
Sitaxentan—Nausea—Levothyroxine—hypothyroidism	0.00185	0.00292	CcSEcCtD
Sitaxentan—Urticaria—Liotrix—hypothyroidism	0.00182	0.00288	CcSEcCtD
Sitaxentan—Body temperature increased—Liotrix—hypothyroidism	0.00181	0.00286	CcSEcCtD
Sitaxentan—EDNRA—G alpha (q) signalling events—TRH—hypothyroidism	0.00176	0.0235	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—TRH—hypothyroidism	0.00174	0.0232	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Liotrix—hypothyroidism	0.00169	0.00267	CcSEcCtD
Sitaxentan—Asthenia—Liotrix—hypothyroidism	0.00164	0.0026	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.00163	0.0217	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.00157	0.021	CbGpPWpGaD
Sitaxentan—Diarrhoea—Liotrix—hypothyroidism	0.00157	0.00248	CcSEcCtD
Sitaxentan—Dizziness—Liotrix—hypothyroidism	0.00152	0.00239	CcSEcCtD
Sitaxentan—Vomiting—Liotrix—hypothyroidism	0.00146	0.0023	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.00145	0.0194	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.00145	0.0194	CbGpPWpGaD
Sitaxentan—Rash—Liotrix—hypothyroidism	0.00144	0.00228	CcSEcCtD
Sitaxentan—Dermatitis—Liotrix—hypothyroidism	0.00144	0.00228	CcSEcCtD
Sitaxentan—Headache—Liotrix—hypothyroidism	0.00144	0.00227	CcSEcCtD
Sitaxentan—Nausea—Liotrix—hypothyroidism	0.00136	0.00215	CcSEcCtD
Sitaxentan—EDNRB—G alpha (q) signalling events—AVP—hypothyroidism	0.00129	0.0172	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—AVP—hypothyroidism	0.00127	0.017	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—TRH—hypothyroidism	0.00124	0.0165	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.00116	0.0155	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.00115	0.0154	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—TSHB—hypothyroidism	0.0011	0.0147	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—TSHR—hypothyroidism	0.0011	0.0147	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.00104	0.0139	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.00104	0.0139	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—AVP—hypothyroidism	0.000923	0.0123	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—AVP—hypothyroidism	0.000912	0.0122	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—TRH—hypothyroidism	0.000887	0.0118	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000854	0.0114	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—POMC—hypothyroidism	0.000847	0.0113	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000826	0.011	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—TSHB—hypothyroidism	0.00079	0.0105	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—TSHR—hypothyroidism	0.00079	0.0105	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—TRH—hypothyroidism	0.0007	0.00935	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—AVP—hypothyroidism	0.000651	0.00869	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—TRH—hypothyroidism	0.000636	0.00849	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—TSHR—hypothyroidism	0.000624	0.00833	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—TSHB—hypothyroidism	0.000624	0.00833	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000612	0.00816	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—POMC—hypothyroidism	0.000606	0.00809	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000568	0.00758	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—TSHB—hypothyroidism	0.000567	0.00756	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—TSHR—hypothyroidism	0.000567	0.00756	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—TRH—hypothyroidism	0.000501	0.00669	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—AVP—hypothyroidism	0.000466	0.00622	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—TRH—hypothyroidism	0.000455	0.00607	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—TSHB—hypothyroidism	0.000447	0.00596	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—TSHR—hypothyroidism	0.000447	0.00596	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CLTC—hypothyroidism	0.000434	0.0058	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—POMC—hypothyroidism	0.000432	0.00577	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000406	0.00543	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—TSHB—hypothyroidism	0.000405	0.00541	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—TSHR—hypothyroidism	0.000405	0.00541	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—VAV3—hypothyroidism	0.000382	0.0051	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TRH—hypothyroidism	0.000376	0.00501	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—AVP—hypothyroidism	0.000368	0.00491	CbGpPWpGaD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000359	0.0048	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—VAV3—hypothyroidism	0.000347	0.00463	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TSHB—hypothyroidism	0.000335	0.00447	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TSHR—hypothyroidism	0.000335	0.00447	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—AVP—hypothyroidism	0.000334	0.00446	CbGpPWpGaD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000328	0.00438	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CLTC—hypothyroidism	0.000311	0.00415	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—POMC—hypothyroidism	0.000309	0.00413	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SH2B3—hypothyroidism	0.000298	0.00398	CbGpPWpGaD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000291	0.00389	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—VAV3—hypothyroidism	0.000273	0.00365	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TRH—hypothyroidism	0.000269	0.00359	CbGpPWpGaD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000266	0.00355	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—AVP—hypothyroidism	0.000263	0.00351	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—VAV3—hypothyroidism	0.000248	0.00331	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—POMC—hypothyroidism	0.000244	0.00326	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TSHB—hypothyroidism	0.00024	0.0032	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TSHR—hypothyroidism	0.00024	0.0032	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—AVP—hypothyroidism	0.000239	0.00319	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—POMC—hypothyroidism	0.000222	0.00296	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PRL—hypothyroidism	0.000221	0.00295	CbGpPWpGaD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000216	0.00289	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SH2B3—hypothyroidism	0.000214	0.00285	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—VAV3—hypothyroidism	0.000205	0.00273	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AVP—hypothyroidism	0.000197	0.00263	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—IYD—hypothyroidism	0.000183	0.00244	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000175	0.00234	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—POMC—hypothyroidism	0.000175	0.00233	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—IYD—hypothyroidism	0.000167	0.00222	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—POMC—hypothyroidism	0.000159	0.00212	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PRL—hypothyroidism	0.000158	0.00211	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ATP5O—hypothyroidism	0.000155	0.00207	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—POMC—hypothyroidism	0.000155	0.00207	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—VAV3—hypothyroidism	0.000147	0.00196	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TPO—hypothyroidism	0.000146	0.00195	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ATP5O—hypothyroidism	0.000142	0.00189	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AVP—hypothyroidism	0.000141	0.00188	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—POMC—hypothyroidism	0.000141	0.00188	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000135	0.00181	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TPO—hypothyroidism	0.000133	0.00178	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—POMC—hypothyroidism	0.000131	0.00175	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IGF1—hypothyroidism	0.000126	0.00168	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000123	0.00165	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—IYD—hypothyroidism	0.00011	0.00147	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—POMC—hypothyroidism	9.38e-05	0.00125	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ATP5O—hypothyroidism	9.34e-05	0.00125	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—POMC—hypothyroidism	9.31e-05	0.00124	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IGF1—hypothyroidism	9.02e-05	0.0012	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TPO—hypothyroidism	8.78e-05	0.00117	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TSHB—hypothyroidism	6.76e-05	0.000902	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TSHB—hypothyroidism	6.16e-05	0.000823	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PIK3C2A—hypothyroidism	6.02e-05	0.000804	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	5.94e-05	0.000794	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PIK3C2A—hypothyroidism	5.49e-05	0.000733	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	5.42e-05	0.000724	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC5A5—hypothyroidism	5.06e-05	0.000676	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC5A5—hypothyroidism	4.61e-05	0.000616	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TSHB—hypothyroidism	4.06e-05	0.000543	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	3.62e-05	0.000484	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC5A5—hypothyroidism	3.04e-05	0.000406	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—POMC—hypothyroidism	2.65e-05	0.000353	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—POMC—hypothyroidism	2.41e-05	0.000322	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—POMC—hypothyroidism	1.59e-05	0.000213	CbGpPWpGaD
